Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Rockwell Medical (RMTI) over the last 16 years, with Dec 2024 value amounting to $15.7 million.

  • Rockwell Medical's Cash & Equivalents rose 10.31% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 10.31%. This contributed to the annual value of $15.7 million for FY2024, which is 74.35% up from last year.
  • Latest data reveals that Rockwell Medical reported Cash & Equivalents of $15.7 million as of FY2024, which was up 74.35% from $9.0 million recorded in FY2023.
  • In the past 5 years, Rockwell Medical's Cash & Equivalents ranged from a high of $48.7 million in FY2020 and a low of $9.0 million during FY2023.
  • Its 3-year average for Cash & Equivalents is $11.6 million, with a median of $10.1 million in 2022.
  • As far as peak fluctuations go, Rockwell Medical's Cash & Equivalents spiked by 312.73% in 2020, and later crashed by 72.72% in 2021.
  • Rockwell Medical's Cash & Equivalents (Yearly) stood at $48.7 million in 2020, then slumped by 72.72% to $13.3 million in 2021, then declined by 23.93% to $10.1 million in 2022, then decreased by 11.08% to $9.0 million in 2023, then surged by 74.35% to $15.7 million in 2024.